• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恢复期血浆治疗 COVID-19:临床经验和疗效。

Convalescent plasma to treat COVID-19: clinical experience and efficacy.

机构信息

Hunan Engineering Research Center of Obstetrics and Gynecological Disease, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.

Department of Dermatology, Hunan Engineering Research Center of Skin Heath and Disease, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.

出版信息

Aging (Albany NY). 2021 Mar 18;13(6):7758-7766. doi: 10.18632/aging.202795.

DOI:10.18632/aging.202795
PMID:33735836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8034927/
Abstract

The recent outbreak of COVID-19 in the world is currently a big threat to global health and economy. Convalescent plasma has been confirmed effective against the novel corona virus in preliminary studies. In this paper, we first described the therapeutic schedule, antibody detection method, indications, contraindications of the convalescent plasmas and reported the effectiveness of convalescent plasma therapy by a retrospective cohort study.

摘要

近期在全球范围内爆发的 COVID-19 疫情,目前是对全球卫生和经济的一大威胁。初步研究已经证实恢复期血浆对新型冠状病毒具有治疗效果。本文首先描述了恢复期血浆的治疗方案、抗体检测方法、适应证、禁忌证,并通过回顾性队列研究报告了恢复期血浆治疗的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ef/8034927/ca18606f51e7/aging-13-202795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ef/8034927/73593b5c919c/aging-13-202795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ef/8034927/ca18606f51e7/aging-13-202795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ef/8034927/73593b5c919c/aging-13-202795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ef/8034927/ca18606f51e7/aging-13-202795-g002.jpg

相似文献

1
Convalescent plasma to treat COVID-19: clinical experience and efficacy.恢复期血浆治疗 COVID-19:临床经验和疗效。
Aging (Albany NY). 2021 Mar 18;13(6):7758-7766. doi: 10.18632/aging.202795.
2
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.一项随机、多中心、开放性 II 期概念验证临床试验,旨在研究恢复期血浆联合 COVID-19 住院患者标准治疗的临床疗效和安全性:捐赠抗体对抗新型冠状病毒(DAWn-Plasma)试验。
Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0.
3
SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.严重急性呼吸综合征冠状病毒2变体与康复期血浆:现实、谬误与机遇
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI148832.
4
Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.新冠病毒感染的恢复期血浆疗法:来自严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒和甲型H1N1流感感染的经验教训
Acta Med Indones. 2021 Jan;53(1):86-95.
5
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.恢复期血浆疗法治疗 COVID-19 患者:抗体检测方法评估及其与中和抗体水平的相关性。
Transfus Med. 2021 Jun;31(3):167-175. doi: 10.1111/tme.12746. Epub 2020 Dec 17.
6
Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.康复期血浆捐献者体内抗SARS-CoV-2血清抗体随时间下降。
Transfusion. 2021 Feb;61(2):651-654. doi: 10.1111/trf.16172.
7
The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients.血清特异性 SARS-CoV-2 抗体在 COVID-19 患者中的作用。
Int Immunopharmacol. 2021 Feb;91:107325. doi: 10.1016/j.intimp.2020.107325. Epub 2020 Dec 24.
8
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.SARS-CoV-2 RNA 持续阳性的患者从恢复期血浆治疗中获益:一项回顾性研究。
Virol Sin. 2020 Dec;35(6):768-775. doi: 10.1007/s12250-020-00281-8. Epub 2020 Aug 31.
9
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.在 B 细胞耗竭患者中使用恢复期血浆成功治疗 COVID-19 感染可能会促进细胞免疫。
Eur J Immunol. 2021 Oct;51(10):2478-2484. doi: 10.1002/eji.202149277. Epub 2021 Sep 3.
10
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.2020 年 2 月至 3 月,中国武汉的 2 家中心对 24 例 COVID-19 肺炎患者进行了恢复期血浆治疗效果的回顾性研究。
Med Sci Monit. 2020 Dec 2;26:e928755. doi: 10.12659/MSM.928755.

引用本文的文献

1
Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.伊马替尼治疗COVID-19患者的疗效和安全性:一项系统评价和荟萃分析。
Wien Klin Wochenschr. 2025 Jun 19. doi: 10.1007/s00508-025-02552-4.
2
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.恢复期人免疫血浆衍生外泌体的临床前研究:对 SARS-CoV-2 的组学和抗病毒特性。
Front Immunol. 2022 Mar 24;13:824378. doi: 10.3389/fimmu.2022.824378. eCollection 2022.
3
Immunological Approaches to the Treatment of New Coronavirus Infection (Review).

本文引用的文献

1
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.康复血浆治疗新冠病毒病:可能性与挑战
JAMA. 2020 Apr 28;323(16):1561-1562. doi: 10.1001/jama.2020.4940.
2
COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.COVID-19:中西医结合管理 2019 年新型冠状病毒病的流行病学、临床、预防和治疗证据及指南的最新进展。
Am J Chin Med. 2020;48(3):737-762. doi: 10.1142/S0192415X20500378. Epub 2020 Mar 13.
3
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
免疫治疗新型冠状病毒感染的方法(综述)。
Sovrem Tekhnologii Med. 2021;13(3):81-99. doi: 10.17691/stm2021.13.3.09. Epub 2021 Jun 28.
4
Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key.用于2019冠状病毒病的恢复期血浆:剂量是关键。
J Transl Int Med. 2021 Jul 9;9(2):68-70. doi: 10.2478/jtim-2021-0029. eCollection 2021 Jun.
5
Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.恢复期血浆治疗 COVID-19 的死亡率获益:一项系统评价与荟萃分析
Front Med (Lausanne). 2021 Apr 9;8:624924. doi: 10.3389/fmed.2021.624924. eCollection 2021.
6
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.通过标准化病毒中和试验定量针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的绝对中和滴度,可实现2019冠状病毒病(COVID-19)血清的跨队列比较。
mBio. 2021 Feb 16;12(1):e02492-20. doi: 10.1128/mBio.02492-20.
7
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.2019年冠状病毒病(COVID-19)的治疗综述:药物重新利用与未满足的临床需求
Front Pharmacol. 2020 Nov 17;11:584956. doi: 10.3389/fphar.2020.584956. eCollection 2020.
8
Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis.COVID-19 重症和危重症患者恢复期血浆治疗的安全性和有效性:系统评价和荟萃分析。
Aging (Albany NY). 2020 Dec 15;13(1):1498-1509. doi: 10.18632/aging.202195.
9
Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.康复期血浆治疗新冠病毒病:应对新发传染病的广谱治疗方法
Microorganisms. 2020 Nov 5;8(11):1733. doi: 10.3390/microorganisms8111733.
10
Convalescent Plasma Therapy for COVID-19: State of the Art.恢复期血浆疗法治疗 COVID-19:最新进展。
Clin Microbiol Rev. 2020 Aug 12;33(4). doi: 10.1128/CMR.00072-20. Print 2020 Sep 16.
中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
4
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.恢复期血浆治疗可降低严重大流行流感 A(H1N1)2009 病毒感染患者的死亡率。
Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.
5
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.严重急性呼吸综合征(SARS)患者恢复期血浆与持续大剂量甲基强的松龙治疗的回顾性比较。
Clin Microbiol Infect. 2004 Jul;10(7):676-8. doi: 10.1111/j.1469-0691.2004.00956.x.